The CCTS congratulates the accomplishments of the following awardees:
Principal Investigator/Institution |
Project Title | Accomplishments |
Yuping Bao, PhD, Univ. Alabama (Tuscaloosa) | Drug screening nanoplatform for ion-gated channel receptors | Evaluated a drug screening platform based on cell membrane coated iron oxide superparticles, established analytic protocols and tested known ion channel binders (blockers & activators) on voltage gated sodium ion channel, Nav1.5. Also established the patch clamp testing platform for ion channel activity evaluation (2) |
Mark Gillespie, PhD, Univ. South Alabama | Production of Mitochondrial (mt)-targeted DNA Repair Proteins | Developed protein production and purification methods. Successfully produced hundreds of milligrams of mitochondrially-targeted recombinant DNA repair fusion protein constructs that have been tested in intact porcine models of multiple organ dysfunction and kidney transplant and in human cultured cell populations |
Adam Keeton, PhD, Univ. South Alabama | Development of human organoid models of colon cancer for therapeutic evaluation of a novel highly potent and selective Ras inhibitor, MCI-062 | Procured a collection of organoids and developed an informatics workflow to implement advanced 3D culture methods to assess anticancer activity of MCI-062 and novel analogs |
Sadis Matalon, PhD, Univ. Alabama at Birmingham | Hemopexin mitigates acute and chronic lung injury in toxic gas inhalation | Demonstrated the effectiveness of hemopexin to reverse pulmonary edema following acute lung injury resulting from cell free heme |
Summer Thyme, PhD, Univ. Alabama at Birmingham | High-Throughput Imaging-Based Screens for Drugs that Correct Neurodevelopmental Abnormalities | Optimized aspects of zebrafish behavioral and brain imaging screening platform and computational workflows to advance patient-driven, genetics-based therapeutic development (3) |
Qin Wang, MD, PhD, Univ. Alabama at Birmingham | Identification of specific α2AAR signaling blockers for Alzheimer’s disease treatment | Determined β-arrestin-dependent, pathological effect of GSK3β activation using Eurofins DiscoverX pre-engineered cell lines & assay kits and confirmed pharmacological properties of known α2AAR antagonists to advance HTS for novel compounds |